Gefitinib and irinotecan in patients with fluoropyrimidine-refractory irinotecan-naïve advanced colorectal cancer (CRC): dose-finding, pharmacokinetics, safety and efficacy

Tamas Hickish,Ian Chau,A. Massey,L. Higgins,R. Osborne,N Botwood,A Swaisland,David Cunningham

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory irinotecan-naïve advanced colorectal cancer (CRC): dose-finding, pharmacokinetics, safety and efficacy

2016

Tamas Hickish
Ian Chau
A. Massey
L. Higgins
R. Osborne
N Botwood
A Swaisland
David Cunningham

13520 Background: Gefitinib (IRESSA) is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has shown supra-additive activity in human CRC xenografts when combined with i...

Keywords:

Gefitinib
Cancer research
Irinotecan
Pathology
Refractory
Colorectal cancer
Tyrosine-kinase inhibitor
Epidermal growth factor receptor
Pharmacokinetics
Medicine
dose finding
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations